

ESTTA Tracking number: **ESTTA704190**

Filing date: **10/23/2015**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Applicant:	<b>GM Pharmaceuticals, Inc.</b>
Application Serial Number:	<b>86527496</b>
Application Filing Date:	<b>02/06/2015</b>
Mark:	<b>VANATOL</b>
Date of Publication	<b>06/30/2015</b>

## 60 Day Request for Extension of Time to Oppose Upon Consent

Pursuant to 37 C.F.R. Section 2.102, GlaxoSmithKline Consumer Healthcare (UK), IP Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UNITED KINGDOM respectfully requests that he/she/it be granted an additional 60-day extension of time to file a notice of opposition against the above-identified mark with applicant's consent.

The party filing this request is related to the party filing the previous request as follows: The initial 90-day Request for Extension of Time to Oppose inadvertently misidentified #Charles M. Atkinson# as the potential opposer. This misidentification was made through a clerical mistake as Charles M. Atkinson is the name of an employee of the true potential opposer, GlaxoSmithKline Consumer Healthcare (UK) IP Limited, on whose behalf he filed the initial extension request. The fact that Mr. Atkinson's name was included by mistake is clear from the rest of the initial request which lists the company's address at #980 Great West Road, Brentford, Middlesex, TW8 9GS, UNITED KINGDOM# and indicates that the intended potential opposer is a private company organized under the laws of England. In addition, the correspondence address indicates that Mr. Atkinson is with GlaxoSmithKline. Therefore, in accordance with 37 CFR Â§ 2.102(b) and TBMP Â§ 206.03, we respectfully request that this mistake be corrected and that GlaxoSmithKline Consumer Healthcare (UK) IP Limited rather than its employee be identified as the proper potential opposer. See also Davidson v. Instantype, Inc., 165 USPQ 269, 271 (TTAB 1970) (leave to amend to substitute proper party granted where opposition was filed in name of the individual rather in the name of the corporation). In addition, please note that due to the limitations in the online form, the name of the potential opposer had to be inputted on two lines and as a result an additional comma appears in the name. The correct name of the potential opposer is GlaxoSmithKline Consumer Healthcare (UK) IP Limited .

The time within which to file a notice of opposition is set to expire on 10/28/2015. GlaxoSmithKline Consumer Healthcare (UK), IP Limited respectfully requests that the time period within which to file an opposition be extended until 12/27/2015.

Respectfully submitted,  
/Charles M. Atkinson/  
10/23/2015

**Charles M. Atkinson**

**GlaxoSmithKline**

**LGTM - NY0300,5 Crescent Drive**

**Philadelphia, PA 19112**

**UNITED STATES**

**trademarks@gsk.com**

**484-431-5142**